Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis reveals rezivertinib provides better treatment outcomes in patients with lung cancer, indicating potential for broader use.
Rezivertinib demonstrates significantly better cost-effectiveness compared to gefitinib for first-line treatment of EGFR-mutated advanced NSCLC in China.
No takes yet. Share an insight, caveat, or question.
Kou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: